Reset filter
Mots-clés
Adverse event ×
Afficher plus Mots-clés
Table des matières
  1. 1. Klinische studie
  2. 2. Routinedocumentatie
  3. 3. Register-/kohortstudies
  4. 4. Kwaliteitswaarborging
  5. 5. Datastandaard
  6. 6. Patiëntenvragenlijst
  7. 7. Medisch vakgebied
Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

904 Résultats de recherche.
Pertinence Commentaire Plus récent Moins récent

TISS Day 16 and Adverse Events Day 13 to 16 Intermittent Prone Positioning Posttraumatic Lung Injury Study

- 03-10-16 - 1 Formulaire, 10 Groupes Item, 43 Eléments de données, 1 Langue
Groupes Item: Patient identification, TISS, TISS ventilation, Cardiovascular Support, Kidney supportive measures, Neurologic, Specific intervention, Adverse Events Day 13 to 16, Serious adverse event Day 13 to 16, Other
Intermittent prone positioning in the treatment of severe and moderate posttraumatic lung injury (1999). Background: Severe posttraumatic lung injury is characterized by impairment of gas exchange and pulmonary densities. The influence of intermittent prone positioning on pulmonary gas exchange and parenchymal densities was investigated prospectively in patients with pulmonary injury after multiple trauma with blunt chest trauma. Publication granted by Claudia Ose, ZKS UK Essen. Multizentrische prospektive randomisierte Studie zur Überprüfung der prognostischen und therapeutischen Effektivität der dorsoventralen Wechsellagerung bei Patienten mit posttraumatischem akutem Lungenversagen. Freigegeben durch Frau Claudia Ose, ZKS Essen.

TISS Day 12 and Adverse Events Day 9 to 12Intermittent Prone Positioning Posttraumatic Lung Injury Study

- 03-10-16 - 1 Formulaire, 10 Groupes Item, 43 Eléments de données, 1 Langue
Groupes Item: Patient identification, TISS, TISS ventilation, Cardiovascular Support, Kidney supportive measures, Neurologic, Specific intervention, Adverse Events Day 9 to 12, Serious adverse event 9 to 12, Other
Intermittent prone positioning in the treatment of severe and moderate posttraumatic lung injury (1999). Background: Severe posttraumatic lung injury is characterized by impairment of gas exchange and pulmonary densities. The influence of intermittent prone positioning on pulmonary gas exchange and parenchymal densities was investigated prospectively in patients with pulmonary injury after multiple trauma with blunt chest trauma. Publication granted by Claudia Ose, ZKS UK Essen. Multizentrische prospektive randomisierte Studie zur Überprüfung der prognostischen und therapeutischen Effektivität der dorsoventralen Wechsellagerung bei Patienten mit posttraumatischem akutem Lungenversagen. Freigegeben durch Frau Claudia Ose, ZKS Essen.

TISS Day 28 and Adverse Events Day 25 to 28 Intermittent Prone Positioning Posttraumatic Lung Injury Study

- 03-10-16 - 1 Formulaire, 10 Groupes Item, 43 Eléments de données, 1 Langue
Groupes Item: Patient identification, TISS, TISS ventilation, Cardiovascular Support, Kidney supportive measures, Neurologic, Specific intervention, Adverse Events Day 25 to 28, Serious adverse event 25 to 28, Other
Intermittent prone positioning in the treatment of severe and moderate posttraumatic lung injury (1999). Background: Severe posttraumatic lung injury is characterized by impairment of gas exchange and pulmonary densities. The influence of intermittent prone positioning on pulmonary gas exchange and parenchymal densities was investigated prospectively in patients with pulmonary injury after multiple trauma with blunt chest trauma. Publication granted by Claudia Ose, ZKS UK Essen. Multizentrische prospektive randomisierte Studie zur Überprüfung der prognostischen und therapeutischen Effektivität der dorsoventralen Wechsellagerung bei Patienten mit posttraumatischem akutem Lungenversagen. Freigegeben durch Frau Claudia Ose, ZKS Essen.

TISS Day 34 and Adverse Events Day 29 to 34 Intermittent Prone Positioning Posttraumatic Lung Injury Study

- 03-10-16 - 1 Formulaire, 10 Groupes Item, 43 Eléments de données, 1 Langue
Groupes Item: Patient identification, TISS, TISS ventilation, Cardiovascular Support, Kidney supportive measures, Neurologic, Specific intervention, Adverse Events Day 29 to 34, Serious adverse event 29 to 34, Other
Intermittent prone positioning in the treatment of severe and moderate posttraumatic lung injury (1999). Background: Severe posttraumatic lung injury is characterized by impairment of gas exchange and pulmonary densities. The influence of intermittent prone positioning on pulmonary gas exchange and parenchymal densities was investigated prospectively in patients with pulmonary injury after multiple trauma with blunt chest trauma. Publication granted by Claudia Ose, ZKS UK Essen. Multizentrische prospektive randomisierte Studie zur Überprüfung der prognostischen und therapeutischen Effektivität der dorsoventralen Wechsellagerung bei Patienten mit posttraumatischem akutem Lungenversagen. Freigegeben durch Frau Claudia Ose, ZKS Essen.

TISS Day 8 and Adverse Events Day 5 to 8 Intermittent Prone Positioning Posttraumatic Lung Injury Study

- 03-10-16 - 1 Formulaire, 10 Groupes Item, 43 Eléments de données, 1 Langue
Groupes Item: Patient identification, TISS, TISS ventilation, Cardiovascular Support, Kidney supportive measures, Neurologic, Specific intervention, Adverse Events Day 5 to 8, Serious adverse event Day 5 to 8, Other
Intermittent prone positioning in the treatment of severe and moderate posttraumatic lung injury (1999). Background: Severe posttraumatic lung injury is characterized by impairment of gas exchange and pulmonary densities. The influence of intermittent prone positioning on pulmonary gas exchange and parenchymal densities was investigated prospectively in patients with pulmonary injury after multiple trauma with blunt chest trauma. Publication granted by Claudia Ose, ZKS UK Essen. Multizentrische prospektive randomisierte Studie zur Überprüfung der prognostischen und therapeutischen Effektivität der dorsoventralen Wechsellagerung bei Patienten mit posttraumatischem akutem Lungenversagen. Freigegeben durch Frau Claudia Ose, ZKS Essen.

TISS Day 4 and Adverse Events Day 1 to 4 Intermittent Prone Positioning Posttraumatic Lung Injury Study

- 03-10-16 - 1 Formulaire, 10 Groupes Item, 43 Eléments de données, 1 Langue
Groupes Item: Patient identification, TISS, TISS ventilation, Cardiovascular Support, Kidney supportive measures, Neurologic, Specific intervention, Adverse Events Day 1 to 4, Serious adverse event Day 1 to 4, Other
Intermittent prone positioning in the treatment of severe and moderate posttraumatic lung injury (1999). Background: Severe posttraumatic lung injury is characterized by impairment of gas exchange and pulmonary densities. The influence of intermittent prone positioning on pulmonary gas exchange and parenchymal densities was investigated prospectively in patients with pulmonary injury after multiple trauma with blunt chest trauma. Publication granted by Claudia Ose, ZKS UK Essen. Multizentrische prospektive randomisierte Studie zur Überprüfung der prognostischen und therapeutischen Effektivität der dorsoventralen Wechsellagerung bei Patienten mit posttraumatischem akutem Lungenversagen. Freigegeben durch Frau Claudia Ose, ZKS Essen.

TISS and Adverse Events Day 0 Intermittent Prone Positioning Posttraumatic Lung Injury Study

- 29-09-16 - 1 Formulaire, 11 Groupes Item, 46 Eléments de données, 1 Langue
Groupes Item: Patient identification, TISS, TISS ventilation, Cardiovascular Support, Kidney supportive measures, Neurologic, Metabolic support, Specific intervention, Adverse Events, Serious adverse event, Other
Intermittent prone positioning in the treatment of severe and moderate posttraumatic lung injury (1999). Background: Severe posttraumatic lung injury is characterized by impairment of gas exchange and pulmonary densities. The influence of intermittent prone positioning on pulmonary gas exchange and parenchymal densities was investigated prospectively in patients with pulmonary injury after multiple trauma with blunt chest trauma. Publication granted by Claudia Ose, ZKS UK Essen. Multizentrische prospektive randomisierte Studie zur Überprüfung der prognostischen und therapeutischen Effektivität der dorsoventralen Wechsellagerung bei Patienten mit posttraumatischem akutem Lungenversagen. Freigegeben durch Frau Claudia Ose, ZKS Essen.

Adverse events LenaMain-Study - Adverse Events CTC

- 17-03-16 - 1 Formulaire, 1 Groupe Item, 24 Eléments de données, 1 Langue
Groupe Item: Adverse Events
A randomised comparison of daily 25 mg versus 5 mg lenalidomide as maintenance therapy after high-dose therapy and autologous stem cell transplantation in patients with multiple myeloma. Protocol-Code: RV-MM-PI-280 EudraCT-Number: 2007-003945-33 Author: Claus Schreiber Review: Gerd Felder Approval of CRF: Prof. Dr. med. G. Kobbe (LKP) Release for MDM: Prof. Gattermann, Düsseldorf (26.1.2016) Principal Investigator „LenaMain“-Studie: Prof. Roland Fenk, Düsseldorf Coordinating center for clinical trial Medical faculty of University Hospital Heinrich-Heine-University Scientific Director: Herr Dr. J. Grebe Moorenstrasse 5 40225 Düsseldorf Tel.: +49 (0) 211-81-19701 Fax: +49 (0) 211-81-19702

Long-Term Follow-Up Assessment, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425 - Long-Term Follow-Up Assessment, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425

- 01-08-16 - 1 Formulaire, 4 Groupes Item, 28 Eléments de données, 1 Langue
Groupes Item: Follow-Up Assessment, Radiology, Adverse Events, Long-Term Follow-Up Adverse Events
Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc (OSI Pharmaceuticals) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of study: Long-Term Follow-Up Assessment

Immunogenicity and safety of hepatitis B vaccine when administered intramuscularly to healthy infants in their first two weeks of life (103860/277) - Follow-up-studies; Study conclusion; Investigator signature; Tracking Document Safety Follow-Up; Serious Adverse Event Safety Follow-Up

- 17-10-19 - 1 Formulaire, 16 Groupes Item, 83 Eléments de données, 1 Langue
Groupes Item: Administration, Follow-up studies, Study conclusion, Investigator signature, Tracking Document Safety Follow-Up, Tracking Document Safety Follow-Up , Serious adverse event safety follow-up - Administrative, Serious adverse event safety follow-up, Serious adverse event safety follow-up - Study vaccine information, Serious adverse event safety follow-up - Concomitant medication/ Vaccination that could have contributed to this SAE, Serious adverse event safety follow-up - Relevant intercurrent illness & medical history that could have contributed to this SAE , Serious adverse event safety follow-up - Drug(s) used to treat this SAE , Serious adverse event safety follow-up - Surgical treatment for this SAE , Serious adverse event safety follow-up - Description , Serious adverse event safety follow-up - Comments , Serious adverse event safety follow-up - Investigator signature
Study ID: 103860/277 Clinical Study ID: 103860/277 Study Title: Phase III study of immunogenicity and safety of 3 doses of GSK Biologicals' thimerosal-free hepatitis B vaccine compared to the US-licensed GSK Biologicals' preservative-free hepatitis B vaccine when administered intramuscularly on a 0, 1, 6-month schedule to healthy infants in their first two weeks of life Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Sponsor: GlaxoSmithKline Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Hepatitis B Vaccine, Recombinant Trade Name: BIO HBV; Engerix-B Study Indication: Hepatitis B

GSK Biologicals' 2-dose thiomersal-free Engerix™-B and 3-dose preservative-free Engerix™-B vaccines Study ID: 101695 NCT00343915 - Long term follow-up, Visit 6 Month 30, Serious adverse events

- 24-03-18 - 1 Formulaire, 6 Groupes Item, 48 Eléments de données, 1 Langue
Groupes Item: Serious adverse events, Study vaccine information, Concomitant medication / vaccination, Intercurrent illness & medical history, Drug(s) used to treat SAE, SAE administative information
Long term follow-up, Visit 6 Month 30, Serious adverse events Study ID: 101695 Ext. Mth30 Clinical Study ID: 101695 Study Title: Long-term study of immune response persistence of GSK Biologicals' 2-dose thiomersal-free Engerix™-B and 3-dose preservative-free Engerix™-B vaccines in subjects aged 11-15 yrs Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00343915 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Hepatitis B Vaccine, Recombinant Trade Name: BIO HBV; Engerix-B Study Indication: Hepatitis B

CCR 2011 Template - Adverse Events

- 15-07-17 - 1 Formulaire, 1 Groupe Item, 30 Eléments de données, 1 Langue
Groupe Item: Adverse Events
This CRF is an ongoing form to capture all adverse events experienced by the patient regardless of the course. Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=ACE96AD5-85FB-D37F-E040-BB89AD43168A

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial